Clinical Trial Update: Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 dose-ranging trial evaluating a T-cell add-back product depleted of host alloreactive cells in patients receiving haploidentical peripheral …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Diseases
• Hematologic Malignancies

Drugs mentioned

• T-cell add-back depleted of host alloreactive cells (investigational product for haploidentical PBSC transplant)

Snippet

Sponsor: Kiadis Pharma | Conditions: Hematologic Diseases, Hematologic Malignancies | Phase 1, Phase 2 | Status: COMPLETED